LIN vs PMCB · P/E 34, rev $33.99B vs $8.6M cap
Linde plc Ordinary Shares (LIN) versus PharmaCyte Biotech Inc (PMCB) — a side-by-side from cached financials, not a winner call.
Linde plc Ordinary Shares (LIN) is a specialty chemicals company listed on US.
PharmaCyte Biotech Inc (PMCB) is a biotechnology company listed on NASDAQ.
Latest reported LIN revenue for 2025-12-31 was $33.99B. Net income was $6.90B. Revenue was up 3.0% from 2024-12-31 to 2025-12-31. LIN currently screens at market cap $223.87B and trailing P/E 34.5.
Latest reported PMCB revenue for 2025-04-30 was $0. Net income was $30.7M. PMCB currently screens at market cap $8.6M.
LIN currently screens at market cap $223.87B and trailing P/E 34.5. PMCB currently screens at market cap $8.6M.
Not investment advice. Open the LIN and PMCB stock pages for the full models.
Not investment advice.